Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best healthcare stocks to buy for 2026.
Teva Pharmaceutical Industries Ltd (TEVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 611,345 | $19,080,078 | -16% | 3.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.86 | 1,113 | $20,988.06 | 13,027 | 2025-09-05 | Filing | |
| $9.60 | 104,500 | $1,003,409.00 | 220,442 | 2019-06-04 | Filing | |
| $8.98 | 111,000 | $997,013.10 | 115,942 | 2019-06-03 | Filing | |
| $21.92 | 2,000 | $43,840.00 | 6,445 | 2018-08-03 | Filing | |
| $19.32 | 250,000 | $4,829,700.00 | 1,500,000 | 2018-05-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.20 | 12,300 | $371,504.28 | 5,650 | 2025-12-16 | Filing | |
| $30.24 | 77,400 | $2,340,645.66 | 367,600 | 2025-12-16 | Filing | |
| $28.68 | 115,468 | $3,311,125.73 | 48,384 | 2025-12-09 | Filing | |
| $28.70 | 98,168 | $2,817,676.84 | 52,828 | 2025-12-09 | Filing | |
| $28.75 | 118,724 | $3,413,077.55 | 150,996 | 2025-12-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,277,986 | $133,515,930 | 0.02% | |
| 2. | 2,172,748 | $67,811,465 | 0.09% | |
| 3. | 1,987,392 | $62,026,504 | 0.04% | |
| 4. | 1,875,521 | $58,535,011 | 8.11% | |
| 5. | 1,824,127 | $56,456,731 | 0.09% |
News See All
12 Best Healthcare Stocks to Buy for 2026
Artificial Intelligence has been the catalyst behind the blockbuster rally in equity markets over the past two years.
Jim Cramer’s Takes on 19 Stocks and Navigating Market Shortages
When in doubt, ask if there's a shortage or a glut of what the company in question sells. If it's the former, then you can buy. And if it's the latter, you better get out of dodge.
What Makes Teva Pharmaceuticals (TEVA) a Successful Brand?
Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2025 Earnings Call Transcript January 28, 2026Teva Pharmaceutical Industries Limited beats earnings expectations.
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025.
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now.
10 Best Affordable Healthcare Stocks to Buy Now
According to him, this has been a year where certain areas of healthcare, particularly those related to health spend or real significant turnarounds in business, have performed pretty well, allowing certain...
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight
TheFly reported on December 9 that Bank of America Securities analyst Jason Gerberry reaffirmed a Buy rating on TEVA and raised his price target to $32.00, reflecting conviction that the stock remains...
Hedge Fund Resource Center Billionaire Hedge Funds
